Morning all,
Recently jumped in around Feb, doubled up on Monday after sighting Matthew Bakers piece regarding ALA presenting to AACR on the 16th April.
So what have we got here?
There seems to be only 4 INKT Cell Therapy companies globally with allergenic off the shelf scalability, with the other three worth at least x 4 ALA.
From what I can tell, the pre clinical data looks exceptional, has secondary remission in the brain ever been seen before?
The new chairman rathered shares instead of cash, presenting to AACR in a matter of weeks and then results expected from the collab with IMU in the next few months.
Trading wise the selling seems sparse with plenty of off screen buying.
Can't help but feel we're in for an exciting six month period.
Add to My Watchlist
What is My Watchlist?
